{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:43:53Z","timestamp":1778273033342,"version":"3.51.4"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1007\/s11926-007-0020-3","type":"journal-article","created":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T01:34:39Z","timestamp":1180748079000},"page":"36-43","source":"Crossref","is-referenced-by-count":31,"title":["Cardiovascular risk, hypertension, and NSAIDs"],"prefix":"10.1007","volume":"9","author":[{"given":"William B.","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,6,3]]},"reference":[{"key":"20_CR1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"F.E. Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000, 284:1247\u20131255.","journal-title":"JAMA"},{"key":"20_CR2","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C. Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520\u20131528.","journal-title":"N Engl J Med"},{"key":"20_CR3","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","volume":"286","author":"D. Mukherjee","year":"2001","unstructured":"Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286:954\u2013959.","journal-title":"JAMA"},{"key":"20_CR4","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1161\/hc4401.100078","volume":"104","author":"M.A. Konstam","year":"2001","unstructured":"Konstam MA, Weir MR, Reicin A, et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001, 104:2280\u20132288.","journal-title":"Circulation"},{"key":"20_CR5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"R.S. Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092\u20131102.","journal-title":"N Engl J Med"},{"key":"20_CR6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa050330","volume":"352","author":"N.A. Nussmeier","year":"2005","unstructured":"Nussmeier NA, Whelton AA, Brown MT, et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081\u20131091.","journal-title":"N Engl J Med"},{"key":"20_CR7","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/9550","volume":"5","author":"D.W. Gilroy","year":"1999","unstructured":"Gilroy DW, Colville-Nash PR, Willis D, et al.: Inducible cyclooygenase may have anti-inflammatory properties. Nat Med 1999, 5:698\u2013701.","journal-title":"Nat Med"},{"key":"20_CR8","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.2174\/0929867043363668","volume":"11","author":"W. Kiefer","year":"2004","unstructured":"Kiefer W, Dannhardt G: Novel insights and therapeutic applications in the field of inhibitors of COX-2. Curr Med Chem 2004, 11:3147\u20133161.","journal-title":"Curr Med Chem"},{"key":"20_CR9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/10408360091174286","volume":"37","author":"E. Fosslien","year":"2000","unstructured":"Fosslien E: Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000, 37:431\u2013502.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"20_CR10","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/01.HYP.0000140925.73081.4c","volume":"44","author":"C.M. Hao","year":"2004","unstructured":"Hao CM, Breyer MD: Hypertension and cyclooxygenase inhibitors. Target: The renal medulla. Hypertension 2004, 44:396\u2013397.","journal-title":"Hypertension"},{"key":"20_CR11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-201X.2004.01329.x","volume":"181","author":"R.C. Harris","year":"2004","unstructured":"Harris RC, Zhang MZ, Cheng HF: Cyclooxygenase-2 and the renal angiotensin system. Acta Physiol Scand 2004, 181:543\u2013547.","journal-title":"Acta Physiol Scand"},{"key":"20_CR12","doi-asserted-by":"crossref","unstructured":"Fries S, Grosser T: The cardiovascular pharmacology of COX-2 inhibition. Hematology Am Soc Hematol Educ Program 2005:445\u201351.","DOI":"10.1182\/asheducation-2005.1.445"},{"key":"20_CR13","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/01.RES.0000170888.11669.28","volume":"96","author":"R.D. Rudic","year":"2005","unstructured":"Rudic RD, Brinster D, Cheng Y, et al.: COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 2005, 96:1240\u20131247.","journal-title":"Circ Res"},{"key":"20_CR14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.CIR.0000153386.95356.78","volume":"111","author":"K.M. Egan","year":"2005","unstructured":"Egan KM, Wang M, Lucin MB, et al.: Cyclooxygenases, thromboxane, and atherosclerosis: Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005, 111:334\u2013342.","journal-title":"Circulation"},{"key":"20_CR15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cmet.2005.08.005","volume":"2","author":"H. Francois","year":"2005","unstructured":"Francois H, Athirakul K, Howell D, et al.: Prostacyclin protects againsts elevated blood pressure and cardiac fibrosis. Cell Metab 2005, 2:201\u2013207.","journal-title":"Cell Metab"},{"key":"20_CR16","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/01.RES.0000153150.27690.f2","volume":"96","author":"K. Rabausch","year":"2005","unstructured":"Rabausch K, Bretschneider E, Sarbia M, et al.: Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2 derived prostaglandins. Circ Res 2005, 96:e1\u2013e6.","journal-title":"Circ Res"},{"key":"20_CR17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0008-6363(02)00414-5","volume":"55","author":"R. Bolli","year":"2002","unstructured":"Bolli R, Shinmura K, Tang XL: Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia\/reperfusion injury and mediates the late phase of pre-conditioning. Cardiovasc Res 2002, 55:506\u2013519.","journal-title":"Cardiovasc Res"},{"key":"20_CR18","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.105.568451","volume":"112","author":"E.M. Antman","year":"2005","unstructured":"Antman EM, DeMets D, Loscalzo J: Cyclooxygenase inhibition and CV risk. Circulation 2005, 112:759\u2013770.","journal-title":"Circulation"},{"key":"20_CR19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1124\/jpet.104.077644","volume":"312","author":"A. Virdis","year":"2005","unstructured":"Virdis A, Colucci R, Fornai M, et al.: Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: Role of inducible nitric-oxide synthase and oxidative stress. J Pharmacol Exp Ther 2005, 312:945\u2013953.","journal-title":"J Pharmacol Exp Ther"},{"key":"20_CR20","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1161\/01.CIR.0000160358.63804.C9","volume":"111","author":"J. Steffel","year":"2005","unstructured":"Steffel J, Hermann M, Greutert H, et al.: Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 2005, 111:1685\u20131689.","journal-title":"Circulation"},{"key":"20_CR21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/archinte.165.2.161","volume":"165","author":"J.R. Sowers","year":"2005","unstructured":"Sowers JR, White WB, Pitt B, et al.: The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis and type 2 diabetes. Arch Intern Med 2005, 165:161\u2013168.","journal-title":"Arch Intern Med"},{"key":"20_CR22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archinte.1993.00410040045007","volume":"153","author":"J.E. Pope","year":"1993","unstructured":"Pope JE, Anderson JJ, Felson DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993, 153:477\u2013484.","journal-title":"Arch Intern Med"},{"key":"20_CR23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-121-4-199408150-00011","volume":"121","author":"A.G. Johnson","year":"1994","unstructured":"Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121:289\u2013300.","journal-title":"Ann Intern Med"},{"key":"20_CR24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/01.HYP.0000149684.01903.b8","volume":"45","author":"S.A. Grover","year":"2005","unstructured":"Grover SA, Coupal L, Zowall H: Treating osteoarthritis with cyclooxygenase-2 specific inhibitors: What are the benefits of avoiding blood pressure destabilization? Hypertension 2005, 45:92\u201397.","journal-title":"Hypertension"},{"key":"20_CR25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/archinte.160.2.149","volume":"160","author":"W.B. White","year":"2000","unstructured":"White WB: Benefits of antihypertensive therapy in older patients with hypertension. Arch Intern Med 2000, 160:149\u2013150.","journal-title":"Arch Intern Med"},{"key":"20_CR26","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","volume":"283","author":"ALLHAT OfficersCoordinators for the ALLHAT Collaborative Research Group.","year":"2000","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000, 283:1967\u20131975.","journal-title":"JAMA"},{"key":"20_CR27","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S. Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high CV risk treated with regimens based on valsart an or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022\u20132031.","journal-title":"Lancet"},{"key":"20_CR28","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0895-7061(00)01204-8","volume":"13","author":"T.O. Morgan","year":"2000","unstructured":"Morgan TO, Anderson A, Bertram D: Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000, 13:1161\u20131167.","journal-title":"Am J Hypertens"},{"key":"20_CR29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1067\/mcp.2002.126182","volume":"72","author":"J.I. Schwartz","year":"2002","unstructured":"Schwartz JI, Vandormael K, Malice MP, et al.: Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002, 72:50\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"20_CR30","first-page":"1501","volume":"29","author":"L.S. Simon","year":"2002","unstructured":"Simon LS, Smolen JS, Abramson SB, et al.: Controversies in COX-2 selective inhibition. J Rheumatol 2002, 29:1501\u20131510.","journal-title":"J Rheumatol"},{"key":"20_CR31","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1016\/S0002-9343(99)00369-1","volume":"107","author":"D.C. Brater","year":"1999","unstructured":"Brater DC: Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 1999, 107:65S\u201370S.","journal-title":"Am J Med"},{"key":"20_CR32","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/archinte.160.10.1465","volume":"160","author":"A. Whelton","year":"2000","unstructured":"Whelton A, Schulman G, Wallemark C, et al.: Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000, 160:1465\u20131470.","journal-title":"Arch Intern Med"},{"key":"20_CR33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0002-9149(02)02661-9","volume":"90","author":"A. Whelton","year":"2002","unstructured":"Whelton A, White WB, Bello AE, et al.: Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002, 90:959\u2013963.","journal-title":"Am J Cardiol"},{"issue":"5B","key":"20_CR34","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/S0002-9343(99)00113-8","volume":"106","author":"A. Whelton","year":"1999","unstructured":"Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999, 106(5B):13S\u201324S.","journal-title":"Am J Med"},{"key":"20_CR35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1172\/JCI0214752","volume":"110","author":"Z. Qi","year":"2002","unstructured":"Qi Z, Hao CM, Langenbach RI, et al.: Opposite effects of cyclooxygenase-1 and-2 activity on the pressor response to angiotensin II. J Clin Invest 2002, 110:61\u201369.","journal-title":"J Clin Invest"},{"key":"20_CR36","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1161\/01.CIR.0000101683.30157.0B","volume":"108","author":"M. Hermann","year":"2003","unstructured":"Hermann M, Camici G, Fratton A, et al.: Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003, 108:2308\u20132311.","journal-title":"Circulation"},{"key":"20_CR37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/01.HYP.0000153053.82032.bf","volume":"45","author":"M. Hermann","year":"2005","unstructured":"Hermann M, Shaw S, Kiss E, et al.: Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension 2005, 45:193\u2013197.","journal-title":"Hypertension"},{"key":"20_CR38","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.21540","volume":"54","author":"B. Hinz","year":"2006","unstructured":"Hinz B, Dormann H, Brune K: More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 2006, 54:282\u2013291.","journal-title":"Arthritis Rheum"},{"key":"20_CR39","first-page":"P2","volume":"11","author":"L.K. Winner","year":"2005","unstructured":"Winner LK, Elliot DJ, Miners JO, Knights KM: In vitro glucoronidation of aldosterone by human liver and kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UCT) 287: inhibition by non-steroidal anti-inflammatory drugs (NSAIDs). Proc Aust Soc Clin Exp Pharmacol Toxicol 2005, 11:P2\u201302.","journal-title":"Proc Aust Soc Clin Exp Pharmacol Toxicol"},{"key":"20_CR40","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2125.2006.02678.x","volume":"61","author":"K.M. Knights","year":"2006","unstructured":"Knights KM, Mangoni AA, Minors JO: Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime? Br J Clin Pharmacol 2006, 61:738\u2013740.","journal-title":"Br J Clin Pharmacol"},{"key":"20_CR41","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/01.HYP.0000014323.99765.16","volume":"39","author":"W.B. White","year":"2002","unstructured":"White WB, Kent J, Taylor A, et al.: Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002, 39:929\u2013934.","journal-title":"Hypertension"},{"key":"20_CR42","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/01.HYP.0000115921.55353.e0","volume":"43","author":"M. Izhar","year":"2004","unstructured":"Izhar M, Alausa T, Folker A, et al.: Effects of COX-inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension 2004, 43:574\u2013577.","journal-title":"Hypertension"},{"key":"20_CR43","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/archinte.1995.00430100075009","volume":"155","author":"M.C. Houston","year":"1995","unstructured":"Houston MC, Weir M, Gray J, et al.: The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995, 155:1049\u20131054.","journal-title":"Arch Intern Med"},{"key":"20_CR44","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(04)16299-5","volume":"363","author":"M. Mamdani","year":"2004","unstructured":"Mamdani M, Juurlink DN, Lee DS, et al.: Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004, 363:1751\u20131756.","journal-title":"Lancet"},{"key":"20_CR45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0002-9149(01)02265-2","volume":"89","author":"W.B. White","year":"2002","unstructured":"White WB, Faich G, Whelton A, et al.: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002, 89:425\u2013430.","journal-title":"Am J Cardiol"},{"key":"20_CR46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9149(03)00659-3","volume":"92","author":"W.B. White","year":"2003","unstructured":"White WB, Faich G, Borer JS, Makuch RW: CV thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003, 92:411\u2013418.","journal-title":"Am J Cardiol"},{"key":"20_CR47","unstructured":"White WB, West CR, Borer JS, et al.: Risk of CV events in patients receiving celecoxib. A metanalysis of randomized clinical trials. Am J Cardiol 2006, in press."},{"key":"20_CR48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","volume":"308","author":"Collaborative overview of randomized trials of antiplatelet therapy","year":"1994","unstructured":"Collaborative overview of randomized trials of antiplatelet therapy: I: prevention of death, myocardial infarction, and stroke. Antiplatelet Trialists\u2019 Collaboration. BMJ 1994, 308:81\u2013106.","journal-title":"BMJ"},{"key":"20_CR49","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)16894-3","volume":"364","author":"M.E. Farkouh","year":"2004","unstructured":"Farkouh ME, Kirshner H, Harrington RA, et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004, 364:675\u2013684.","journal-title":"Lancet"},{"key":"20_CR50","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(05)17864-7","volume":"365","author":"D.J. Graham","year":"2005","unstructured":"Graham DJ, Campen D, Hui R, et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475\u2013481.","journal-title":"Lancet"},{"key":"20_CR51","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1161\/CIRCULATIONAHA.106.616219","volume":"113","author":"G.H. Gislason","year":"2006","unstructured":"Gislason GH, Jacobsen S, Rasmussen JN, et al.: Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective non-steroidal antiinflammatory drugs after acute infarction. Circulation 2006, 113:2906\u20132913.","journal-title":"Circulation"},{"key":"20_CR52","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","volume":"296","author":"P. McGettigan","year":"2006","unstructured":"McGettigan P, Henry D: Cardiovascular risk and inhibition of cyclooxygenases: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase-2. JAMA 2006, 296:1633\u20131644.","journal-title":"JAMA"},{"key":"20_CR53","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/CIRCULATIONAHA.105.595793","volume":"113","author":"A.T. Chan","year":"2006","unstructured":"Chan AT, Manson JE, Albert CM, et al.: Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006, 113:1578\u20131587.","journal-title":"Circulation"},{"key":"20_CR54","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"S.D. Solomon","year":"2005","unstructured":"Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071\u20131080.","journal-title":"N Engl J Med"},{"key":"20_CR55","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa061355","volume":"355","author":"M.M. Bertagnolli","year":"2006","unstructured":"Bertagnolli MM, Eagle CJ, Zauber AG, et al.: Celecoxib for the prevention of colorectal adenomas. N Engl J Med 2006, 355:873\u2013884.","journal-title":"N Engl J Med"},{"key":"20_CR56","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa061652","volume":"355","author":"N. Arber","year":"2006","unstructured":"Arber N, Eagle CJ, Spicak J, et al.: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355:885\u2013895.","journal-title":"N Engl J Med"},{"issue":"SupplIII","key":"20_CR57","first-page":"85","volume":"64","author":"G. Singh","year":"2005","unstructured":"Singh G, Mithal A, Triadafilopoulos G: Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient not the drug class. Ann Rheum Dis 2005, 64(Suppl III):85.","journal-title":"Ann Rheum Dis"},{"key":"20_CR58","first-page":"S57","volume":"14","author":"M.C. Sturkenboom","year":"2005","unstructured":"Sturkenboom MC, Dieleman J, Verhamme K, et al.: Cardiovascular events during use of COX-2 selective and non-selective NSAIDs. Pharmacoepidemiol Drug Saf 2005, 14:S57.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"20_CR59","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/bmj.330.7504.1366","volume":"330","author":"J. Hippisley-Cox","year":"2005","unstructured":"Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclooxygenase inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005, 330:1366\u20131372.","journal-title":"BMJ"},{"key":"20_CR60","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archinte.165.9.978","volume":"165","author":"S.P. Johnsen","year":"2005","unstructured":"Johnsen SP, Larsson H, Tarone RE, et al.: Risk of hospitalisation for myocardial infarction among users of rofecoxib, celecoxib and other NSAIDs: a population based case control study. Arch Intern Med 2005, 165:978\u2013984.","journal-title":"Arch Intern Med"},{"key":"20_CR61","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7326\/0003-4819-142-7-200504050-00113","volume":"142","author":"L.E. Levesque","year":"2005","unstructured":"Levesque LE, Brophy JM, Zhang B: The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005, 142:481\u2013489.","journal-title":"Ann Intern Med"},{"key":"20_CR62","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jacc.2003.08.064","volume":"43","author":"S.E. Kimmel","year":"2004","unstructured":"Kimmel SE, Berlin JA, Reilly M, et al.: The effects of non-selective non-aspirin non-steroidal anti-inflammatory medications on the risk of non-fatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004, 43:985\u2013990.","journal-title":"J Am Coll Cardiol"},{"key":"20_CR63","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-142-3-200502010-00005","volume":"142","author":"S.E. Kimmel","year":"2005","unstructured":"Kimmel SE, Berlin JA, Reilly M, et al.: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005, 142:157\u2013164.","journal-title":"Ann Intern Med"},{"key":"20_CR64","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(02)11131-7","volume":"360","author":"W.A. Ray","year":"2002","unstructured":"Ray WA, Stein CM, Daugherty JR, et al.: Cyclo-oxygenase-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002, 360:1071\u20131073.","journal-title":"Lancet"},{"key":"20_CR65","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(02)07370-1","volume":"359","author":"W.A. Ray","year":"2002","unstructured":"Ray WA, Stein CM, Hall K, et al.: Non-steroidal anti-inflammatory drugs and the risk of serious coronary heart disease: an observational cohort study. Lancet 2002, 359:118\u2013123.","journal-title":"Lancet"},{"key":"20_CR66","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1001\/archinte.164.22.2472","volume":"164","author":"L.M. Fischer","year":"2004","unstructured":"Fischer LM, Schlienger RG, Matter CM, et al.: Discontinuation of non-steroidal anti-inflammatory drug therapy and the risk of acute myocardial infarction. Arch Intern Med 2004, 164:2472\u20132476.","journal-title":"Arch Intern Med"},{"key":"20_CR67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1741-7015-3-17","volume":"3","author":"L.A. Garcia Rodriguez","year":"2005","unstructured":"Garcia Rodriguez LA, Gonzalez-Perez A: Long-term use of traditional of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005, 3:17.","journal-title":"BMC Med"},{"key":"20_CR68","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/01.STR.0000053029.45352.A0","volume":"34","author":"S. Bak","year":"2003","unstructured":"Bak S, Andersen M, Tsiropoulos I, et al.: Risk of stroke associated with non-steroidal anti-inflammatory drugs. Stroke 2003, 34:379\u2013386.","journal-title":"Stroke"},{"key":"20_CR69","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/archinte.162.10.1099","volume":"162","author":"D.H. Solomon","year":"2002","unstructured":"Solomon DH, Glynn RJ, Levin R, Avorn J: Non-steroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002, 162:1099\u20131104.","journal-title":"Arch Intern Med"},{"key":"20_CR70","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1365-2125.2002.01637.x","volume":"54","author":"R.G. Schlienger","year":"2002","unstructured":"Schlienger RG, Jick H, Meier CR: Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol 2002, 54:327\u2013332.","journal-title":"Br J Clin Pharmacol"},{"key":"20_CR71","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/archinte.162.10.1105","volume":"162","author":"D.J. Watson","year":"2002","unstructured":"Watson DJ, Rhodes T, Cai B, Guess HA: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002, 162:1105\u20131110.","journal-title":"Arch Intern Med"},{"key":"20_CR72","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","volume":"361","author":"T.M. MacDonald","year":"2003","unstructured":"MacDonald TM, Wei L: Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003, 361:573\u2013574.","journal-title":"Lancet"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-007-0020-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-007-0020-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-007-0020-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:49:46Z","timestamp":1559422186000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-007-0020-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["20"],"URL":"https:\/\/doi.org\/10.1007\/s11926-007-0020-3","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}